Korean Market Expertise
Over the past couple of years, we have seen huge growth in the pharma and biotech industries in Asia, and especially in Korea.
Historically, the Korean pharmaceutical industry was built on manufacturing and generics capabilities, however, in the past few decades many more innovative technologies and products have emerged.
Viewed as the next semi-conductor industry, and therefore a significant boost to the economy and a generator of large numbers of high value jobs, higher numbers of Korean companies and investors have become very active in new drug and technology development – with significant support from the Korean government.
How can we help you?
PharmaVentures has an expert team including Korean-speakers, working in this emerging market to help you explore the new business opportunities that Korea has to offer.
Meet our Korean-speaking experts at the following events to discuss new business opportunities.
9-11 June 2021
Dr Fintan Walton, Founder & CEO at PharmaVentures alongside Dr Adrian Dawkes, Managing Director and Luke Lee, Associate will be presenting.
24 June 2021
Dr Adrian Dawkes, Managing Director and Luke Lee, Associate, will be presenting.
Global Licensing Seminar II : The Impact of COVID-19 and Analysis of Licensing Deals
Special COVID-19 Session: COVID-19 impact on the biopharmaceutical global licensing landscape and how to maximise attendance at digital partnering events (SP)
Licensing deal structures: what to think of when negotiating (AD)
Analysis of various licensing deals (SP/AD)
Global Licensing Seminar I : Basic Process and Negotiations
BD101: how to do licensing deals for beginners
Licensing deal negotiations for a successful partnership
Global licensing deal trends and what this means for Korean biopharma companies